NCT00642655View on ClinicalTrials.gov

Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Kidney Transplant

Interventions

DRUG

IVIG and Rituximab

IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22

Trial Locations (1)

90048

8700 Beverly Blvd., Los Angeles

Sponsors

Collaborators (2)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Biogen

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER